Abstract
To assess the efficacy of a new investigative treatment a non-inferiority study is undertaken when it is no longer ethical to have a placebo control. Instead an active controlled trial is undertaken. The objective is thus to show that the new treatment is no worse than the active control. In analysing a non-inferiority trial, the following ABC needs to be considered [1]: 1. The Assay sensitivity of the active control in both the placebo controlled trials and in the active controlled non-inferiority trial is the same. 3. Bias is minimised through steps such as ensuring that the patient population and the primary efficacy endpoint are essentially the same for the placebo-controlled trial and the active-controlled trial.